Biopharmaceutical stocks that have lagged behind the broader market may finally have their day in the sun. BofA Securities ...

Amgen, a leading American biopharmaceutical company, is set to invest $200 million in a new Technology and Innovation Centre.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

global head of development for Sandoz Biopharmaceuticals. Amgen company is seeking to defend its osteoporosis franchise with UCB-partnered Evenity (romosozumab), an anti-sclerostin antibody that ...

The partners are building toward a regulatory submission for Tezspire in chronic rhinosinusitis with nasal polyps in the ...

Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...

Amgen and CytomX Therapeutics have kicked a phase 1 T-cell engager to the curb, axing the asset after assessing the clinical data and their pipeline priorities. CytomX signaled the EGFRxCD3 ...

Eikon is building a high-profile line of potential drugs. Its portfolio is led by EIK-1001, which is just rolling out a ...

Amgen has a strong commitment to quality ... Manufacturing fundamentals for biopharmaceuticals. In: Jameel F, Hershenson S, eds. Formulation and Process Development Strategies for Manufacturing ...

Amgen Inc., Abbvie Inc., GlaxoSmithKline ... Competition is a key aspect of market research. This Biopharmaceuticals Market report analyzes major and emerging players, assessing market share ...